BRIEF—PureTech sells shares to raise £72 million

London-listed PureTech Health has raised £72 million ($100 million) through a placing of 45 million shares, brokered by Jefferies International.

The firm said the money would be used to advance “growth of our late-stage affiliates through their next value-driving milestones and potentially monetisation events,” and to develop “one or more novel internally-funded clinical-stage assets to Phase II/III status; and advance two or more of our internally-funded, lymphatic-biology focused programmes to the clinic.”

Chief executive Daphne Zohar said the firm boasted “positive pivotal trial results from two affiliates that are now filing for regulatory approvals,” and highlighted “the recent successful NASDAQ IPO of one of our affiliates, and the progression of our clinical pipeline with multiple proof-of-concept readouts and validating partnerships and investments.”